Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$8.79 - $11.51 $65,169 - $85,335
-7,414 Reduced 41.74%
10,350 $118,000
Q3 2023

Nov 13, 2023

SELL
$8.25 - $11.35 $175,997 - $242,129
-21,333 Reduced 54.56%
17,764 $171,000
Q2 2023

Jul 31, 2023

BUY
$10.1 - $11.6 $10,837 - $12,446
1,073 Added 2.82%
39,097 $415,000
Q1 2023

May 10, 2023

SELL
$10.37 - $12.56 $1,700 - $2,059
-164 Reduced 0.43%
38,024 $400,000
Q4 2022

Feb 07, 2023

BUY
$9.9 - $12.43 $34,640 - $43,492
3,499 Added 10.09%
38,188 $473,000
Q3 2022

Nov 14, 2022

BUY
$10.14 - $12.38 $8,456 - $10,324
834 Added 2.46%
34,689 $359,000
Q2 2022

Aug 12, 2022

SELL
$11.05 - $12.72 $55,913 - $64,363
-5,060 Reduced 13.0%
33,855 $390,000
Q1 2022

May 16, 2022

BUY
$10.61 - $12.88 $47,256 - $57,367
4,454 Added 12.92%
38,915 $490,000
Q4 2021

Feb 14, 2022

SELL
$10.86 - $13.95 $40,540 - $52,075
-3,733 Reduced 9.77%
34,461 $402,000
Q3 2021

Nov 15, 2021

BUY
$11.92 - $13.92 $169,609 - $198,067
14,229 Added 59.37%
38,194 $499,000
Q2 2021

Aug 13, 2021

BUY
$10.16 - $13.11 $141,884 - $183,081
13,965 Added 139.65%
23,965 $308,000
Q1 2021

May 14, 2021

BUY
$9.04 - $11.86 $90,399 - $118,600
10,000 New
10,000 $112,000
Q2 2018

Aug 14, 2018

SELL
$11.83 - $16.2 $250,322 - $342,792
-21,160 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$11.13 - $13.63 $32,933 - $40,331
2,959 Added 16.26%
21,160 $326,000
Q4 2017

Feb 14, 2018

SELL
$12.16 - $14.58 $668 - $801
-55 Reduced 0.3%
18,201 $273,000
Q3 2017

Nov 14, 2017

BUY
$12.07 - $14.87 $16,922 - $20,847
1,402 Added 8.32%
18,256 $288,000
Q2 2017

Aug 14, 2017

BUY
N/A
16,854
16,854 $318,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $323M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.